Skip to main content
SpringerLink
Log in

Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects

  • Original Articles
  • Thio-TEPA, TEPA, Pharmacokinetics, Pharmacodynamics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A total of 13 patients with ovarian cancer were studied during the initial two courses of i. v. thio-TEPA treatment they underwent after primary surgery. Following an increase in the dose from 60 to 80 mg for the second course, no sign of saturation of thio-TEPA elimination processes or of formation of the metabolite TEPA occurred, indicating dose-independent pharmacokinetics. Myelosuppression after courses was registered by serial measurements of platelets and leukocytes. The time to platelet nadir was quite uniformly 3 weeks and tended to be longer than that of leukocytes, which averaged 2 weeks but showed greater interindividual variation. Linear regression analyses of pharmacokinetic parameters versus myelosuppression revealed statistically significant correlations between thio-TEPA pharmacokinetics and the percentage of reductions in leukocytes and platelets at their mean nadirs. In contrast, no such correlation could be demonstrated for TEPA despite its greater exposure to the body in terms of AUC. We advocate further investigation of this pharmacokinetic-pharmacodynamic relationship so as to establish individualized dosing of thio-TEPA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD (1988) Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol 6: 1192

    Google Scholar 

  2. Angelli G, De Cunto M, Gresele P, Del Favero A (1982) Early onset life-threatening myelosuppression after low-dose intravesical thiotepa. Postgrad Med J 58: 380

    Google Scholar 

  3. Bateman JC (1955) Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med 252: 879

    Google Scholar 

  4. Boone IU, Rogers BS, Williams DL (1962) Toxicity, metabolism, and tissue distribution of carbon 14-labeledNN′N″-triethylenethiophosphoramide (thio-TEPA) in rats. Toxicol Appl Pharmacol 4: 344

    Google Scholar 

  5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748

    Google Scholar 

  6. Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL (1986) Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 70: 859

    Google Scholar 

  7. Craig AW, Fox BW, Jackson H (1959) Metabolic studies of32P-labeled triethylenethiophosphoramide. Biochem Pharmacol 3: 42

    Google Scholar 

  8. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Critchlow J, Flaherty M, Mick R, Schnipper LE, Frei E III (1988) Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 80: 1221

    Google Scholar 

  9. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432

    Google Scholar 

  10. Friedman OM, Boger E (1961) Colorimetric estimation of nitrogen mustards in aqueous media. Anal Chem 33: 906

    Google Scholar 

  11. Hagen B, Walseth F, Walstad RA, Iversen T (1985) Gas chromatographic assay of triethylenethiophosphoramide in serum and urine. J Chromatogr Biomed Appl 345: 173

    Google Scholar 

  12. Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother Pharmacol 19: 143

    Google Scholar 

  13. Hagen B, Walstad RA, Nilsen OG (1988) Pharmacokinetics of thio-TEPA at two different doses. Cancer Chemother Pharmacol 22: 356

    Google Scholar 

  14. Hagen B, Neverdal G, Walstad RA, Nilsen OG (1990) Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i. v. bolus adminsitration of thio-TEPA in ovarian cancer patients. Cancer Chemother Pharmacol 25: 257

    Google Scholar 

  15. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillespie A, Sam J, Poplack DG (1989) Phase I and pharmacokinetic evaluation of thiotepa in cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49: 736

    Google Scholar 

  16. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K (1987) Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep 71: 1043

    Google Scholar 

  17. Hollister D, Coleman M (1980) Hematologic effects of intravesical thiotepa therapy for bladder carcinoma. JAMA 244: 2065

    Google Scholar 

  18. Kapadia SB, Krause JR (1978) Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy. Cancer 41: 1676

    Google Scholar 

  19. Lazarus HM, Reed MD, Spitzer TR, Salah Rabaa M, Blumer JL (1987) High-dose i. v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71: 689

    Google Scholar 

  20. Lokich JJ, Egorin MJ, Cohen BE, Bern MM, Zipoli TE, Moore C (1989) A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion. Cancer 63: 46

    Google Scholar 

  21. McDermott BJ, Double JA, Bibby MC, Wilman DEV, Loadman PM, Turner RL (1985) Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens. J Chromatogr Biomed Appl 338: 335

    Google Scholar 

  22. Mellet LB, Woods LA (1960) The comparative physiological disposition of thio-TEPA and TEPA in the dog. Cancer Res 20: 524

    Google Scholar 

  23. Tanum G, Sønstevold A, Engeset A (1987) The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA. Blut 54: 33

    Google Scholar 

  24. Waxman DJ, Clarke L, Ng S (1989) Oxidative metabolism of thio-TEPA. Role of hepatic cytochrome P-450. Proc Am Assoc Cancer Res 30: 463

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Department of Pharmacology and Toxicology, University of Trondheim, N-7006, Trondheim, Norway

    Bjørn Hagen

Authors
  1. Bjørn Hagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The work described in this paper was supported by grants from the Cancer Fund at the Regional Hospital (Trondheim) and the Norwegian Cancer Society (Oslo). During this work the author was a research fellow for the Norwegian Cancer Society

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagen, B. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Cancer Chemother. Pharmacol. 27, 373–378 (1991). https://doi.org/10.1007/BF00688860

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00688860

Keywords

Search

Navigation